Literature DB >> 20616696

Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus.

Roberto Flores, James J Goedert.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20616696      PMCID： PMC2930257          DOI： 10.1097/QAD.0b013e32833c7bb8

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  31 in total

1.  Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.

Authors:  Dimitra Bourboulia; Diana Aldam; Dimitrios Lagos; Elizabeth Allen; Ian Williams; David Cornforth; Andrew Copas; Chris Boshoff
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

2.  Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus latency in B cells.

Authors:  Lei Chen; Michael Lagunoff
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.

Authors:  John Wilkinson; Alethea Cope; Jas Gill; Dimitra Bourboulia; Peter Hayes; Nesrina Imami; Toru Kubo; Anne Marcelin; Vincent Calvez; Robin Weiss; Brian Gazzard; Chris Boshoff; Frances Gotch
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Kaposi's sarcoma-associated herpesvirus and innate immunity.

Authors:  John A West; Blossom Damania
Journal:  Future Virol       Date:  2010-03-01       Impact factor: 1.831

Review 5.  Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus.

Authors:  Cristina Aresté; David J Blackbourn
Journal:  Trends Microbiol       Date:  2009-02-18       Impact factor: 17.079

6.  Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.

Authors:  Jasjit Gill; Dimitra Bourboulia; John Wilkinson; Peter Hayes; Alethea Cope; Anne-Genevieve Marcelin; Vincent Calvez; Frances Gotch; Christopher Boshoff; Brian Gazzard
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-01       Impact factor: 3.731

7.  Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma.

Authors:  Eric A Engels; Robert J Biggar; Vickie A Marshall; Michael A Walters; Christine J Gamache; Denise Whitby; James J Goedert
Journal:  AIDS       Date:  2003-08-15       Impact factor: 4.177

Review 8.  Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis.

Authors:  Chengyu Liang; Jong-Soo Lee; Jae U Jung
Journal:  Semin Cancer Biol       Date:  2008-10-02       Impact factor: 15.707

9.  Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma.

Authors:  A Scott Laney; Michael J Cannon; Harold W Jaffe; Margaret K Offermann; Chin-Yih Ou; Kay W Radford; Mitesh M Patel; Thomas J Spira; Clifford J Gunthel; Philip E Pellett; Sheila C Dollard
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

Review 10.  Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?

Authors:  Patrick S Moore; Yuan Chang
Journal:  Annu Rev Microbiol       Date:  2003       Impact factor: 15.500
View more
  5 in total

1.  Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily.

Authors:  Emanuele Amodio; James J Goedert; Patrizia Barozzi; Giovanni Riva; Alberto Firenze; Filippa Bonura; Enza Viviano; Nino Romano; Mario Luppi
Journal:  Cancer Sci       Date:  2011-07-28       Impact factor: 6.716

2.  Antibody responses to lytic and latent human herpesvirus 8 antigens among HIV-infected patients in central China.

Authors:  T J Zhang; N He; Y Y Ding; Q W Jiang; C Wood
Journal:  Biosci Trends       Date:  2012-06       Impact factor: 2.400

3.  Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30.

Authors:  Colleen Pelser; Jaap Middeldorp; Sam M Mbulaiteye; Carmela Lauria; Angelo Messina; Enza Viviano; Nino Romano; Francesco Vitale; James J Goedert
Journal:  Infect Agent Cancer       Date:  2010-10-12       Impact factor: 2.965

4.  Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.

Authors:  Jean-Marc Lacombe; François Boue; Sophie Grabar; Nathalie Viget; Sandrine Gazaignes; Anne-Sophie Lascaux-Cametz; Jérome Pacanowski; Marialuisa Partisani; Odile Launay; Sophie Matheron; Eric Rosenthal; Elisabeth Rouveix; Pierre Tattevin; Pierre de Truchis; Dominique Costagliola; James J Goedert
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

5.  Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls.

Authors:  R M Valenti; E Amodio; J-M Nam; L Preiss; B I Graubard; N Romano; J J Goedert
Journal:  Br J Cancer       Date:  2011-01-18       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.